|
|
Volumn 5, Issue 3, 2004, Pages 160-161
|
|
Emtricitabine/tenofovir disoproxil fumarate
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIRETROVIRUS AGENT;
EMTRICITABINE;
LAMIVUDINE PLUS ZIDOVUDINE;
RNA DIRECTED DNA POLYMERASE INHIBITOR;
TENOFOVIR DISOPROXIL;
ARTICLE;
AUSTRALIA;
BRAZIL;
CANADA;
COMMERCIAL PHENOMENA;
DRUG ACTIVITY;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG FORMULATION;
DRUG INDICATION;
DRUG MARKETING;
DRUG POTENCY;
DRUG SAFETY;
DRUG SENSITIVITY;
DRUG USE;
EUROPEAN UNION;
FOOD AND DRUG ADMINISTRATION;
GENOTYPE;
HEPATITIS B VIRUS;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
ICELAND;
JAPAN;
PHENOTYPE;
PRIORITY JOURNAL;
SWITZERLAND;
TABLET;
UNITED STATES;
VIRUS STRAIN;
ADENINE;
ANTI-HIV AGENTS;
CLINICAL TRIALS;
DEOXYCYTIDINE;
DRUG COMBINATIONS;
DRUGS, INVESTIGATIONAL;
HUMANS;
PHOSPHONIC ACIDS;
|
|
EID: 2942676483
PISSN: 11745886
EISSN: None
Source Type: Journal
DOI: 10.2165/00126839-200405030-00004 Document Type: Article |
|
Times cited : (4)
|
|
References (2)
|
